According to the multi-year renewal agreement, the user base for NextBio is expanded across Boehringer Ingelheim’s global research organization.
NextBio president and chief executive officer Saeid Akhtari said, "This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide."
The integration of proprietary analysis results with curated content enables researchers’ ability to design experiments, test hypotheses and validate results, resulting in improved target analysis, understanding of disease mechanisms, and analysis of results across species.
NextBio Research offers a platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research, according to the company.